Laboratory Corp. of America Holdings (LH) Shares Bought by BRYN MAWR TRUST Co

BRYN MAWR TRUST Co increased its holdings in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 2.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 31,842 shares of the medical research company’s stock after purchasing an additional 665 shares during the period. BRYN MAWR TRUST Co’s holdings in Laboratory Corp. of America were worth $5,079,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. LPL Financial LLC boosted its position in Laboratory Corp. of America by 7.6% in the 4th quarter. LPL Financial LLC now owns 4,081 shares of the medical research company’s stock valued at $652,000 after buying an additional 290 shares during the last quarter. DnB Asset Management AS raised its stake in shares of Laboratory Corp. of America by 2.7% in the 4th quarter. DnB Asset Management AS now owns 11,474 shares of the medical research company’s stock valued at $1,830,000 after purchasing an additional 300 shares in the last quarter. New Mexico Educational Retirement Board raised its stake in shares of Laboratory Corp. of America by 3.2% in the 4th quarter. New Mexico Educational Retirement Board now owns 9,779 shares of the medical research company’s stock valued at $1,560,000 after purchasing an additional 300 shares in the last quarter. Coastline Trust Co raised its stake in shares of Laboratory Corp. of America by 6.1% in the 4th quarter. Coastline Trust Co now owns 5,400 shares of the medical research company’s stock valued at $861,000 after purchasing an additional 310 shares in the last quarter. Finally, Lido Advisors LLC raised its stake in shares of Laboratory Corp. of America by 12.3% in the 4th quarter. Lido Advisors LLC now owns 2,858 shares of the medical research company’s stock valued at $455,000 after purchasing an additional 312 shares in the last quarter. 92.32% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

In other Laboratory Corp. of America news, CEO David P. King sold 49,967 shares of the business’s stock in a transaction dated Friday, March 23rd. The shares were sold at an average price of $164.75, for a total value of $8,232,063.25. Following the completion of the transaction, the chief executive officer now directly owns 231,202 shares of the company’s stock, valued at $38,090,529.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Adam H. Schechter sold 1,263 shares of Laboratory Corp. of America stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $169.29, for a total transaction of $213,813.27. Following the sale, the director now owns 7,297 shares of the company’s stock, valued at approximately $1,235,309.13. The disclosure for this sale can be found here. Insiders have sold a total of 59,630 shares of company stock valued at $9,851,701 over the last ninety days. 0.73% of the stock is owned by insiders.

NYSE:LH traded up $0.73 during midday trading on Thursday, reaching $164.90. The stock had a trading volume of 591,173 shares, compared to its average volume of 669,311. The company has a current ratio of 1.31, a quick ratio of 1.20 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $16,827.77, a PE ratio of 17.18, a PEG ratio of 1.41 and a beta of 0.94. Laboratory Corp. of America Holdings has a 1-year low of $134.19 and a 1-year high of $181.71.

Laboratory Corp. of America (NYSE:LH) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $2.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.07. The company had revenue of $2.70 billion for the quarter, compared to analyst estimates of $2.70 billion. Laboratory Corp. of America had a net margin of 12.15% and a return on equity of 16.30%. The business’s quarterly revenue was up 13.2% on a year-over-year basis. During the same period last year, the business posted $2.15 EPS. analysts anticipate that Laboratory Corp. of America Holdings will post 11.55 EPS for the current fiscal year.

A number of brokerages have recently issued reports on LH. ValuEngine lowered shares of Laboratory Corp. of America from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Zacks Investment Research upgraded shares of Laboratory Corp. of America from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. Craig Hallum reiterated a “buy” rating and set a $204.00 price objective (up previously from $180.00) on shares of Laboratory Corp. of America in a research note on Wednesday, February 7th. Goldman Sachs started coverage on shares of Laboratory Corp. of America in a research report on Monday, January 29th. They issued a “buy” rating and a $205.00 target price for the company. Finally, Citigroup increased their price objective on shares of Laboratory Corp. of America from $161.00 to $184.00 and gave the company a “neutral” rating in a report on Friday, February 9th. Seven research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $189.19.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Macon Daily and is the sole property of of Macon Daily. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://macondaily.com/2018/04/12/bryn-mawr-trust-co-grows-holdings-in-laboratory-corp-of-america-holdings-lh-updated-updated-updated.html.

About Laboratory Corp. of America

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply